case_images: PMC11774735_01
case_images: (A-C) Chest computed tomography (CT) images; (D-F) corresponding PET/CT scans. (A, D) Baseline imaging before the start of selpercatinib treatment. (B, E) Imaging results 2 months after the start of treatment. (C, F) Chest CT and PET/CT scans after 14 months of treatment with selpercatinib, highlighting changes in disease progression and response to therapy over time.
case_images: fonc-14-1500449-g001.jpg
case_images: PMC11774735_01_fonc-14-1500449-g001.jpg
case_images: f1
case_images: At restaging after 6 months of RET fusion TKI therapy, CT scans documented complete disease response ( Figure 1 ), with no further accumulation of pleural fluid and no evidence of respiratory failure.
case_images: Patient timeline. This figure illustrates the chronological overview of the patient's treatment and corresponding response, from the baseline in November 2021 through to the time of exit in December 2023. It highlights key points in the patient's clinical course, including treatment interventions, response assessments, and significant changes in health status. CT, computed tomography; CR, complete response.
case_images: fonc-14-1500449-g002.jpg
case_images: PMC11774735_01_fonc-14-1500449-g002.jpg
case_images: f2
case_images: The timeline of treatment is shown in  Figure 2 .